Clinical Trials Logo

Filter by:
NCT ID: NCT05823285 Recruiting - Clinical trials for Advanced Solid Tumors

A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLS31903 in Advanced Solid Tumor Patients

Start date: March 22, 2023
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate safety, pharmacokinetics,immunogenicity and efficacy of QLS31903 alone in the treatment of advanced cancer.

NCT ID: NCT05823272 Recruiting - Gastric Cancer Clinical Trials

ONS in Gastric Cancer After Total Gastrectomy

Start date: March 22, 2024
Phase: N/A
Study type: Interventional

Gastric cancer patients after total gastrectomy will be randomized to oral nutritional supplement group or control group at discharge. Patients will receive 6 months of oral nutritional supplement or normal diet after discharge. The primary and secondary outcomes will be collected.

NCT ID: NCT05823246 Recruiting - Melanoma Clinical Trials

Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma

Start date: April 24, 2023
Phase: Phase 2
Study type: Interventional

This study will assess the safety, tolerability and efficacy of every-2-week dosing of QLF31907 injection in patients with advanced melanoma and urothelial carcinoma.

NCT ID: NCT05822869 Recruiting - Clinical trials for Acute Respiratory Distress Syndrome

Early PP Monitored by EIT in Patients With ARDS

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

Acute Respiratory Distress Syndrome (ARDS) is a syndrome characterized by respiratory distress and refractory hypoxemia caused by pulmonary and extra-pulmonary factors. Despite improvements in diagnosis and treatment in recent years, the mortality rate of severe ARDS is still around 40%. The distribution of lung lesions in ARDS patients is significantly gravity-dependent. Even with lung-protective ventilation strategies, tidal volume is concentrated in the ventral lung region, leading to ventilator-associated lung injury. Prone position ventilation can increase ventilation to the dorsal lung tissue and improve the ventilation-perfusion ratio, thus improving oxygenation. During prone position ventilation in ARDS patients, lung-protective ventilation strategies should be maintained, but with different respiratory mechanics from the supine position, requiring adjustment of ventilator parameters. Electrical Impedance Tomography (EIT) technology can be used for bedside monitoring of mechanically ventilated patients, providing real-time feedback on the patient's ventilation status and having great potential for clinical applications. Investigators believes that EIT monitoring during prone position ventilation in ARDS patients can individualize lung-protective ventilation strategies, minimize alveolar overdistension and collapse, improve the weaning success rate of invasive ventilation, and ultimately improve patient prognosis.

NCT ID: NCT05822843 Recruiting - Clinical trials for B-cell Lymphoid Malignancies

A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies

Start date: August 2, 2023
Phase: Phase 1
Study type: Interventional

This is a phase I, multicenter, open label, sequential-cohort, dose escalation study of ESG206. The purpose is to evaluate the clinical safety, tolerability, PK (pharmacokinetics), and preliminary efficacy and to establish the MTD (maximum tolerated dose), if any, and RP2D (recommended phaseII dose) of ESG206 in adult subjects with B lymphoid malignancies.

NCT ID: NCT05822817 Recruiting - Pituitary Adenoma Clinical Trials

Comparison of Postoperative Recovery of Sevoflurane and Propofol After Transsphenoidal Surgery

Start date: May 3, 2023
Phase: Phase 4
Study type: Interventional

Currently, total intravenous anesthesia (TIVA) and inhaled anesthesia are both commonly used for transsphenoidal pituitary adenoma resection. However, optimal choice for anesthesia maintenance in transsphenoidal surgery remains unclear. Previous studies focusing on this question provided fragmentary assessment and controversial results. The goal of this clinical trial is to investigate whether propofol and sevoflurane have different effect on post-anesthetic recovery after transsphenoidal resection of pituitary adenoma.

NCT ID: NCT05822726 Recruiting - Prostate Cancer Clinical Trials

The Combination of PSMA-PET/MR and p2PSA in Early Diagnosis of Prostate Cancer

Start date: October 1, 2022
Phase: N/A
Study type: Interventional

This is a single center prospective non-randomized controlled study. The goal of this clinical trial is to figure out whether the combination of PSMA-PET/MR and PHI could add values to each method alone. The main questions it aims to answer are: - Compare the diagnostic value of the combination with each alone and set up a diagnostic model. - Compare the diagnostic value of PSMA-PET/MR+PHI to mpMRI+PHI. - Evaluate the diagnostic value the combination of PHI and PSMA-PET/MR in suspected PCA patients. Patients will experience mpMRI or PSMA-PET/MR and their blood samples will be used to test PSA and p2PSA. Prostate biopsy will be the golden standard.

NCT ID: NCT05822635 Recruiting - Pancreatic Diseases Clinical Trials

SpyGlass Surgical Study

Start date: December 1, 2023
Phase:
Study type: Observational

- To document the clinical utility of diagnostic and/or therapeutic intraoperative endoscopy using a thin, single-use, flexible cholangiopancreatoscope - To identify specific surgical procedures in which intraoperative use of a thin, single use, flexible cholangiopancreatoscope suggests clinically meaningful benefit and generate a hypothesis for possible subsequent claims-supportive study

NCT ID: NCT05822050 Recruiting - Clinical trials for PTCL Patients Who Achieved Complete Response From Frontline Treatment

An Open, Single Center, Non-randomized, Single Arm Clinical Study of Evaluating the Efficacy of Selinexor in the Maintenance Treatment of PTCL

Start date: June 1, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

To evaluate the efficacy and safety of Selinexor maintenance therapy in PTCL patients who achieved complete response from frontline treatment, and to analyze the relationship between gene mutation in PTCL and disease prognosis and clinical features by using Next-generation sequencing (NGS) detection.

NCT ID: NCT05822037 Recruiting - Multiple Myeloma Clinical Trials

CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Start date: April 12, 2023
Phase: N/A
Study type: Interventional

This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT0594CP CAR-T Cells in patients with relapsed and/or refractory multiple myeloma or Plasma Cell Leukemia